FILE:DGX/DGX-8K-20090319200118.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
Item 7.01. Regulation FD Disclosure
Pursuant to its existing share repurchase authority, on March 19, 2009, the Company repurchased 4,511,657 shares of its common stock, par value $.01 per share ("Common Stock"), from SB Holdings Capital Inc., a wholly-owned subsidiary of GlaxoSmithKline plc., for an aggregate purchase price of $200,000,013.31. The purchase price for the Common Stock reflected a negotiated discount to the volume-weighted average trading price of the Common Stock in a trading period preceding the purchase.
 
     
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 


